on Darwin AG (isin : DE000A3C35W0)
Darwin AG Reports Significant Revenue Growth for 2025
Darwin AG, a prominent European healthcare company, has announced its preliminary group revenue for 2025, showcasing significant growth. The company recorded consolidated revenue of approximately €55 million, a 117% increase from the previous year's €25.3 million. This impressive growth underscores the operational strength of the group, according to CEO Dr. Daniel Wallerstorfer.
Key contributors to this expansion include the successful international marketing of genetic analysis products and personalized nutritional supplements through its subsidiary, Novogenia GmbH. Strategic partnerships with 10X Health (USA) and M42 (Abu Dhabi) are cited as instrumental in this scaling phase. Darwin AG anticipates continued value creation through these partnerships and future initiatives.
The audited financial figures for 2025 will be published alongside the Annual Report on May 12, 2026.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Darwin AG news